Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00495820 · ClinicalTrials.gov registry record · Phase 4
Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study
A Phase 4 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT00495820: Completed Phase 4 study, sponsored by VA Office of Research and Development.
NCT00495820 is a Phase 4 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00495820, a Phase 4 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the efficacy of methylphenidate over placebo in treating apathy in patients with Alzheimer's dementia. Apathy is one of the earliest and most profound disturbances that occur in Alzheimer's dementia (AD). Hypotheses: 1. Methylphenidate (MPH) will improve apathy significantly more than placebo in AD. 2\. Successful treatment of apathy will improve Instrumental Activities of Daily Living (IADLs), and caregiver burden.
Interventions
- OTHER Placebo
- DRUG Methylphenidate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2007-08 |
| Est. Completion | 2010-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00495820
The ClinicalTrials.gov registry entry for NCT00495820 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00495820 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00495820 about?
NCT00495820 is a clinical study titled "Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study". The purpose of the study is to determine the efficacy of methylphenidate over placebo in treating apathy in patients with Alzheimer's dementia. Apathy is one of the earliest and most profound disturbances that occur in Alzheimer's dementia (AD). Hypotheses: 1. Methylphenidate (MPH) will improve apa...
What is the current status of trial NCT00495820?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2007-08. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00495820?
The interventions under investigation include: Placebo (OTHER), Methylphenidate (DRUG).
Who is sponsoring clinical trial NCT00495820?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.